IGM Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 224
- Market Cap
- $606.8M
- Website
- http://www.igmbio.com
- Introduction
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM a...
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06524687
- Locations
- 🇺🇸
Standford University, Palo Alto, California, United States
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- IGM Biosciences, Inc.
- Registration Number
- NCT06331832
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇰🇷Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
🇪🇸START-Madrid Centro Integral Oncologico Clara Campal, Madrid, Spain
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06087406
- Locations
- 🇺🇸
Anniston Medical Clinic, Anniston, Alabama, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States
🇺🇸Triwest Research Associates, San Diego, California, United States
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06041568
- Locations
- 🇺🇸
Care and Cure Clinic, Houston, Texas, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
🇺🇸East Bay Rheumatology, San Leandro, California, United States
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05908396
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Tennessee Oncology (SCRI), Nashville, Tennessee, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05702424
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Oklahoma University, Norman, Oklahoma, United States
🇺🇸START South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05184218
- Locations
- 🇿🇦
Farmovs, Bloemfontein, Free State, South Africa
Evaluation of IGM-6268 in Healthy Volunteers
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05160402
- Locations
- 🇺🇸
Aventiv Research, Columbus, Ohio, United States
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT04553692
- Locations
- 🇺🇸
Mayo Clinic, Minneapolis, Minnesota, United States
🇺🇸Minnesota Oncology - Minneapolis Clinic, Minneapolis, Minnesota, United States
🇺🇸UCSF, San Francisco, California, United States
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04082936
- Locations
- 🇦🇺
Linear Clinical Resaerch, Nedlands, Western Australia, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
🇺🇸City of Hope, Duarte, California, United States